Trial Profile
Phase I study using BK-UM against HB-EGF [heparin binding EGF-like growth factor] for patients with advanced or recurrent ovarian cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2017
Price :
$35
*
At a glance
- Drugs CRM 197 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; First in man
- 07 May 2008 New trial record.